Immunotherapy for Epstein-Barr virus-associated malignancies.
Epstein-Barr virus (EBV) is present in the malignant cells of several human cancers including post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma, nasopharyngeal carcinoma, natural killer/T lymphomas and Burkitt's lymphoma. Yet in > 90% of the world's adult population, who carry EBV as a lifelong asymptomatic infection, the oncogenic potential of this virus is controlled by a strong virus-specific T-cell response. Accordingly, EBV-associated malignancies represent good candidates for a T-cell-based therapy and provide an important model for developing such therapies for other human cancers. This review summarizes the impressive results seen with T-cell therapy for PTLD and discusses, in the light of recent technological advances, the prospects for developing more effective approaches for other EBV-associated cancers.
Long
Heather M
HM
School of Cancer Sciences, University of Birmingham, Birmingham, UK.
Parsonage
Gregory
G
Fox
Christopher P
CP
Lee
Steven P
SP
D020031:Epstein-Barr Virus Infections / Q000150:complications*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D008232:Lymphoproliferative Disorders / Q000628:therapy* / Q000821:virology; D009369:Neoplasms / Q000628:therapy* / Q000821:virology; D016377:Organ Transplantation / Q000009:adverse effects*; D011948:Receptors, Antigen, T-Cell / Q000502:physiology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D017735:Virus Latency
D011948:Receptors, Antigen, T-Cell